Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
The group’s point-of-care Car-T push looks to have stalled.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Minghui’s MHB088C will soon start phase 3 in China.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
